ACR deal will eliminate global comms difficulties, says GPSI

By Gareth Macdonald

- Last updated on GMT

Related tags: Contract research organization

The new partnership with Indian CRO Abridge Clinical Research (ACR) is a unique collaboration offering cost efficient and timely trial solutions according to Global Pharmaceutical Services (GPSI) spokesperson Keith Russell.

The deal combines ACR’s clinical research capacity with GPSI’s consultation, training and auditing services in a partnership that, they hope, will attract new customers in India and the US.

Russell told Outsoucing-pharma that part of the motivation for setting up the partnership was GPSI’s recognition of the need to build clinical R&D capacity that is attractive to potential sponsors.

Through its’ business activities with US pharma and biotech companies, GPSI had become apprised of the need for the placement of clinical studies in facilities that were conducting clinical studies efficiently and on time, at a reasonable cost and, most importantly, uncompromisingly meeting regulatory guidelines​.”

Dr. Emran Khan, Director of Abridge Clinical Research, was introduced to GPSI by a mutual business colleague. Following several information exchanges including in-depth discussions regarding business philosophies, opportunities for collaboration were identified​.”

Local knowledge

Russell explained that ACR will serve as project manager for all US trial sponsors, identifying the most appropriate service provider based on its knowledge of Indian contract research organizations (CRO).

He added that “Abridge Clinical Research will negotiate the contract directly with the service provider based upon a working proposal generated by the client or by Abridge Clinical Research.

“Contract negotiations will be done by an Abridge Clinical Research representative, in the local language who is knowledgeable of the business environment in India, which will mean a lower overall cost to the client.”

GPSI will act as US project manager for all studies conducted in India, providing clients with a point of contact that will, according to Russell, “eliminate the typical communication difficulties encountered when dealing on an international basis​.”

Related news

Show more

Related products

show more

A Winning End-to-End Solution for Oncology Studies

A Winning End-to-End Solution for Oncology Studies

Clinical Ink | 22-Feb-2021 | Technical / White Paper

Oncology clinical trials present a unique set of challenges for patients, study sites, and study sponsors. Using electronic patient reported outcomes (ePRO)...

Related suppliers

Follow us


View more